Administration of Lenvatinib to patients with anaplastic thyroid cancer

DOI Web Site 13 References Open Access
  • Adachi Naoto
    Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medical Sciences, University of Fukui
  • Kato Yukinori
    Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medical Sciences, University of Fukui
  • Saito Kyoko
    Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medical Sciences, University of Fukui
  • Kanno Masafumi
    Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medical Sciences, University of Fukui
  • Ogi Kazuhiro
    Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medical Sciences, University of Fukui
  • Narita Norihiko
    Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medical Sciences, University of Fukui
  • Fujieda Shigeharu
    Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medical Sciences, University of Fukui

Bibliographic Information

Other Title
  • 当科での甲状腺未分化癌に対するレンバチニブ投与症例の検討

Search this article

Description

The proportion of anaplastic thyroid cancer is only one to two percent of all thyroid cancers. However, multidisciplinary therapy has little effect on the prognosis of anaplastic thyroid cancer. Lenvatinib has been approved in Japan since 2015 as a treatment for patients with unresectable or metastatic thyroid cancer. We administered lenvatinib to nine patients with anaplastic thyroid cancer from October 2015 through January 2017. Two patients were male and seven were female. The mean age of the patients was 74.6 years （with an age range of 54-84）. We investigated the therapeutic effects and adverse events of lenvatinib in these patients with anaplastic thyroid cancer. Six out of the nine patients showed partial response （PR）. One patient survived for more than a year after administration of lenvatinib. In the nine patients administered lenvatinib, the most usual adverse events were hypertension （eight patients）, followed by gastrointestinal symptoms （seven patients）, renal insufficiency （six patients）, thrombocytopenia （four patients）, and fistula formation （three patients）. It is important to continue administering lenvatinib while adjusting the dose depending on the grade of adverse events.

Journal

References(13)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top